Unknown

Dataset Information

0

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.


ABSTRACT: Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic ?-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Like other class B G protein-coupled receptors (GPCRs), the GLP-1R contains an N-terminal extracellular ligand binding domain. N-terminal truncations on the peptide agonist generate antagonists capable of binding to the extracellular domain, but not capable of activating full length receptor. The main objective of this study was to use Hydrogen/deuterium exchange (HDX) to identify how the amide hydrogen bonding network of peptide ligands and the extracellular domain of GLP-1R (nGLP-1R) were altered by binding interactions and to then use this platform to validate direct binding events for putative GLP-1R small molecule ligands. The HDX studies presented here for two glucagon-like peptide-1 receptor (GLP-1R) peptide ligands indicates that the antagonist exendin-4[9-39] is significantly destabilized in the presence of nonionic detergents as compared to the agonist exendin-4. Furthermore, HDX can detect stabilization of exendin-4 and exendin-4[9-39] hydrogen bonding networks at the N-terminal helix [Val19 to Lys27] upon binding to the N-terminal extracellular domain of GLP-1R (nGLP-1R). In addition we show hydrogen bonding network stabilization on nGLP-1R in response to ligand binding, and validate direct binding events with the extracellular domain of the receptor for putative GLP-1R small molecule ligands.

SUBMITTER: West GM 

PROVIDER: S-EPMC4152014 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.

West Graham M GM   Willard Francis S FS   Sloop Kyle W KW   Showalter Aaron D AD   Pascal Bruce D BD   Griffin Patrick R PR  

PloS one 20140902 9


Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic β-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Like other class B G protein-coupled receptors (GPCRs), the GLP-1R contains an N-terminal extracellular ligand binding domain. N-terminal truncations on the peptide agonist generate antagonists capable of binding to the extracellular domain, but not capable of activating full length receptor. The  ...[more]

Similar Datasets

| S-EPMC3446547 | biostudies-literature
| S-EPMC2804221 | biostudies-literature
| S-EPMC6879014 | biostudies-literature
| S-EPMC2581847 | biostudies-literature
| S-EPMC5118412 | biostudies-literature
| S-EPMC2895362 | biostudies-other
| S-EPMC5775921 | biostudies-literature
| S-EPMC4933217 | biostudies-literature
| S-EPMC4342481 | biostudies-literature
| S-EPMC7780097 | biostudies-literature